Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonacog beta pegol in Haemophilia B Surgery
NCT01386528Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2012
- Primary completion
- Dec 2013
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of nonacog beta pegol in hemophilia B (HB), sponsored by Novo Nordisk. Primary endpoint: Haemostatic Effect During Surgery Evaluated by the Four-point Response Scale. Started Jun 2012; status: completed.
02
Drugs
nonacog beta pegol
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT01386528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01386528.